ATO and Melphalan resistance pathways overlap while Doxorubicin resistance pathway(s) may be related.

<p>8226/S, 8226/S-CR, 8226/S-ATOR05 cells, as well as 8226/S-ATOR05 cells cultured in the absence of ATO for 7, 14, 21, 35, and 50 days were treated with the indicated concentrations of ATO, Mel, or Dox for 24 h and apoptosis was determined by flow cytometry and graphed as percent of control Annexin V positive cells versus drug concentration. The data are presented as the mean ± SD of at least 3 independent experiments.